WebMD

Zevaskyn for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Recessive dystrophic epidermolysis bullosa, also called RDEB, is one form of epidermolysis bullosa. Epidermolysis bullosa is a rare genetic condition that causes very fragile skin. With RDEB, even a ...
Monthly Prescribing Reference

FDA’s Decision on Recessive Dystrophic Epidermolysis Bullosa Treatment Delayed

The deficiencies noted in the CRL were not related to efficacy or safety data. The Food and Drug Administration (FDA) has issued a Complete Response Letter to Abeona Therapeutics regarding the ...
Nasdaq

Krystal Biotech, Inc. Doses First Patient in Phase 3 Trial Evaluating KB803 for Corneal Abrasion Treatment in Dystrophic Epidermolysis Bullosa Patients

Krystal Biotech, Inc. has initiated its Phase 3 clinical trial, named IOLITE, to evaluate KB803, a gene therapy designed to treat and prevent corneal abrasions in patients with dystrophic ...
Healio

FDA approves Zevaskyn for treatment of recessive dystrophic epidermolysis bullosa

Please provide your email address to receive an email when new articles are posted on . Recessive dystrophic epidermolysis bullosa is a rare and serious condition. Zevaskyn is the first FDA-approved ...